If you are wondering whether Agilent Technologies at around US$112.75 is starting to look attractively priced, the recent ...

Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q4 2025 investor ...

Agilent Technologies Inc. agreed to acquire privately held Biocare Medical, which makes instruments and materials used in ...

Agilent Technologies Inc. shares are up during Monday’s premarket session as the company announces the acquisition of Biocare ...

Biocare has been under the stewardship of VC firms Excellere Partners and GHO Capital since 2021, achieving revenue of $90m ...

Biocare’s strong growth in immunohistochemistry is expected to strengthen Agilent’s ability to develop new in vitro diagnostic antibodies.

Agilent Technologies (A) has been drawing attention after recent share price weakness, with the stock down about 10% over the past month and 17% over the past 3 months. This has prompted fresh ...

Agilent Technologies said that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal of $950 million ...

Agilent Technologies (NYSE:A) will release its quarterly earnings report on Wednesday, 2025-05-28. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Agilent ...

Agilent acquires Biocare for $950M to boost pathology/cancer diagnostics and recurring revenue. Click here to read an analysis of A stock now.

By Sahil Pandey March 9 (Reuters) - Life sciences firm Agilent Technologies said on Monday that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal valued at ...

Agilent Technologies stock (NYSE: A), which provides instruments and consumables for laboratories, trades at $113 per share, 10% below the level seen in March 2021. Agilent’s stock was trading at ...